Reducing time costs;

Speeding up the R&D process;

Improving the success rate of drug development and shortening time to market for clients.

All core team members have rich experience;

With perfect quality assurance system;

Able to meet customers' needs for China-US dual declaration and global multi-center clinical declaration

Data as of June 30, 2023, it has passed more than 100 on-site inspections by national or local drug regulatory authorities and the FDA;

Equipped with a leading and abundant technology platform;

Actively laying out cutting-edge technologies with first-mover advantage in the field of gene therapy.

Technical talents and resources with unique advantages in various drug R&D service fields, and the management team and PIs are from domestic/international well-known CROs or pharmaceutical companies, who are well versed in domestic and international drug R&D laws and regulations and quality systems to provide customers with high-quality research results.

Xihua has been deeply engaged in bioanalysis since its establishment in 2015, and has accumulated rich experience in the field of bioanalysis, which makes it an industry leader in terms of business scale, quality and reputation in this segment.

We have accumulated rich industry experience and established a good reputation, and successfully expanded the service of providing a full range of new drug development services to large domestic and foreign pharmaceutical companies and many emerging well-known innovative biotechnology companies. Data as of June 30, 2023, the company has served more than 700 domestic and international customers, including both most of top 50 domestic pharmaceutical companies and  the top 10 global pharmaceutical companies, as well as welll-known innovative biotechnology enterprises.